Business Wire

TAIPEI-EXCHANGE

8.6.2022 10:02:10 CEST | Business Wire | Press release

Share
Taipei Exchange (TPEx) Provides a Supportive Ecosystem for Innovation and Sustainable Growth

The Taipei Exchange (TPEx), has successfully built an efficient multi-tiered fund-raising platform to foster the growth of innovative companies within the Taiwan capital market while also focusing on Environmental, Social and Governance (ESG) practices.

Support for Innovation
Along with a Mainboard of well-established companies, TPEx provides an Emerging Stock market, which includes Emerging Stock board and Pioneer Stock board, for companies prior to IPO, and the Go Incubation Board for Startup and Acceleration Firms. This multi-tiered structure aims to support the growth of enterprises through various stages of their development.

In line with Taiwan government policies, TPEx has been devoted to fostering innovative industries, high-tech industries, and small and medium-sized enterprises (SMEs), thus driving the momentum of Taiwan’s economy. Since its establishment 28 years ago, TPEx has assisted more than 2,300 public companies to gain access and contribute to the Taiwan capital market.

Environmental, Social and Governance (ESG) Practices
While providing a convenient mechanism for fundraising, TPEx also assists listed companies in setting their sustainable operations and ESG practices in response to the impact of climate change and international attention to the sustainability issue. As The European Union’s (EU’s) proposed new directive on corporate sustainability reporting (CSRD) is planned to come into effect in January 2023, TPEx has long been engaged in enhancing ESG information transparency, including requiring listed companies to prepare Sustainability reports in accordance with GRI Standards and strengthening the disclosure of Sustainability Reporting with reference to international norms under TCFD and SASB.

TPEx has also made efforts to publish relevant information and guidelines to assist listed companies in strengthening ESG-related disclosure. The rate of listed companies that prepared sustainability reports for 2020 was around 20% and according to the "CG WATCH 2020 Report” from the Asian Corporate Governance Association (ACGA), Taiwan’s concerted effort over the past two years to enhance its CG ecosystem has moved it from fifth to fourth position.

In order to deepen sustainable growth, TPEx has strengthened the function of the board of directors for listed companies and continues to expand the scope of TPEx-listed companies that are required to prepare Sustainability reports. Companies are encouraged to enhance communications with stakeholders, and from June 2023, TPEx-listed companies will also be required to appoint a Chief Governance Officer.

To meet the needs for ESG investing and sustainable financing globally, TPEx has been promoting diversified ESG investment products and responsible investment. TPEx has launched several sustainability-themed indexes to steer market funds toward investments that address climate change and environmental sustainability. The Chairman of TPEx, Philip Chen, stated that, “TPEx commits to upholding ESG values to strengthen our core businesses. TPEx will continue to promote capital raising functionality, innovative and sustainable related products, information transparency, and efficient fair-trading mechanisms; building a vibrant and innovative world-class capital market.”

For more information about the Taipei Exchange, please visit: https://www.tpex.org.tw/web/index.php?l=en-us

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye